Media Center
Press Release
Imperial College London Diabetes Centre, part of Mubadala’s network of healthcare providers, and Abu Dhabi’s one-stop-shop for the treatment, prevention, education and research of diabetes, has announced a new partnership with the International Consortium for Health Outcomes Measurement (ICHOM). The partnership will champion value-based healthcare through the creation of a global standard for diabetes management with a focus on quality of life outcomes for patients. ICLDC and ICHOM will commence their collaborative work this May.
The objective of the new partnership is the development of a standard set of health outcomes, focused on results that matter most to type-2 diabetes patients. The standard sets will serve as a reliable source of data for physicians who can then use the data and incorporate into a patient’s diabetes management plan.
For patients, ‘value-based’ healthcare means safe, appropriate, and effective care with enduring results, at a reasonable cost. For healthcare providers, the system means employing evidence-based medicine and proven treatments and techniques that take into account the patients’ wishes and preferences, as opposed to more traditional approaches to healthcare that often prioritize quotas over outcomes.
Mazen Al Dahmani, Deputy Chief Executive Officer at Imperial College London Diabetes Centre, said, “We are delighted to announce our latest partnership with ICHOM, an initiative that supports the delivery of value-based healthcare as we establish a global standard for type-2 diabetes management. At ICLDC we are at the forefront developing a value-based approach that has the potential for positive change in clinical practices. The partnership arrangement enables us to pool our resources and expertise for the best possible outcome, and is aligned with wider global and regional initiatives in healthcare.”
ICHOM’s President, Dr. Christina Akerman said, "ICHOM is very pleased to have the support of Imperial College London Diabetes Centre on this important initiative. The partnership reflects the commitment of both parties to outcomes measurement as a means of driving value in healthcare and the development of a standard set of outcomes that are meaningful to patients with type-2 diabetes."
For further information about the project and Imperial College London Diabetes Centre’s sponsorship, please visit http://www.ichom.org/medical-conditions/diabetes/ and http://www.ichom.org/sponsoring-partners/
